BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 30668392)

  • 1. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor.
    Dong R; Yang X; Wang C; Liu K; Liu Z; Ma X; Sun H; Huo X; Fu T; Meng Q
    Phytomedicine; 2019 Feb; 53():134-142. PubMed ID: 30668392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice.
    Sun X; Duan X; Wang C; Liu Z; Sun P; Huo X; Ma X; Sun H; Liu K; Meng Q
    Eur J Pharmacol; 2017 Jul; 806():75-82. PubMed ID: 28414056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schaftoside alleviates HFD-induced hepatic lipid accumulation in mice via upregulating farnesoid X receptor.
    Liu M; Zhang G; Wu S; Song M; Wang J; Cai W; Mi S; Liu C
    J Ethnopharmacol; 2020 Jun; 255():112776. PubMed ID: 32205261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yangonin modulates lipid homeostasis, ameliorates cholestasis and cellular senescence in alcoholic liver disease via activating nuclear receptor FXR.
    Kong L; Dong R; Huang K; Wang X; Wang D; Yue N; Wang C; Sun P; Gu J; Luo H; Liu K; Wu J; Sun H; Meng Q
    Phytomedicine; 2021 Sep; 90():153629. PubMed ID: 34304130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation.
    Wang X; Fu T; Wang J; Wang C; Liu K; Wu J; Sun H; Ma X; Sun P; Meng Q
    Int Immunopharmacol; 2019 Oct; 75():105833. PubMed ID: 31450152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
    Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
    Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
    Shen C; Pan Z; Wu S; Zheng M; Zhong C; Xin X; Lan S; Zhu Z; Liu M; Wu H; Huang Q; Zhang J; Liu Z; Si Y; Tu H; Deng Z; Yu Y; Liu H; Zhong Y; Guo J; Cai J; Xian S
    J Ethnopharmacol; 2021 Oct; 279():114340. PubMed ID: 34171397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effects of yangonin from an edible botanical Kava against lithocholic acid-induced cholestasis and hepatotoxicity.
    Kong Y; Gao X; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Sun P; Meng Q
    Eur J Pharmacol; 2018 Apr; 824():64-71. PubMed ID: 29427579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
    Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
    Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model.
    Xu L; Kim JK; Bai Q; Zhang X; Kakiyama G; Min HK; Sanyal AJ; Pandak WM; Ren S
    Mol Pharmacol; 2013 Mar; 83(3):648-58. PubMed ID: 23258548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.
    Schmitt J; Kong B; Stieger B; Tschopp O; Schultze SM; Rau M; Weber A; Müllhaupt B; Guo GL; Geier A
    Liver Int; 2015 Apr; 35(4):1133-1144. PubMed ID: 25156247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
    Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
    Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of calycosin against high-fat diet-induced nonalcoholic fatty liver disease in mice.
    Duan X; Meng Q; Wang C; Liu Z; Sun H; Huo X; Sun P; Ma X; Peng J; Liu K
    J Gastroenterol Hepatol; 2018 Feb; 33(2):533-542. PubMed ID: 28699662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal ethanol exposure programs an increased susceptibility of non-alcoholic fatty liver disease in female adult offspring rats.
    Shen L; Liu Z; Gong J; Zhang L; Wang L; Magdalou J; Chen L; Wang H
    Toxicol Appl Pharmacol; 2014 Jan; 274(2):263-73. PubMed ID: 24275070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
    Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
    Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gracilaria chorda subcritical water ameliorates hepatic lipid accumulation and regulates glucose homeostasis in a hepatic steatosis cell model and obese C57BL/6J mice.
    Thakuri LS; Park CM; Kim HA; Kim HJ; Park JW; Park JC; Rhyu DY
    J Ethnopharmacol; 2024 Feb; 320():117395. PubMed ID: 37952731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.
    Fu D; Cui H; Zhang Y
    Cell Physiol Biochem; 2018; 45(6):2187-2198. PubMed ID: 29550812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Green tea polyphenols ameliorate non-alcoholic fatty liver disease through upregulating AMPK activation in high fat fed Zucker fatty rats.
    Tan Y; Kim J; Cheng J; Ong M; Lao WG; Jin XL; Lin YG; Xiao L; Zhu XQ; Qu XQ
    World J Gastroenterol; 2017 Jun; 23(21):3805-3814. PubMed ID: 28638220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Swertiamarin ameliorates oleic acid induced lipid accumulation and oxidative stress by attenuating gluconeogenesis and lipogenesis in hepatic steatosis.
    Patel TP; Rawal K; Soni S; Gupta S
    Biomed Pharmacother; 2016 Oct; 83():785-791. PubMed ID: 27490779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.